Fucosidosis

Mendelian MONDO:0009254 Pathograph 47 Oligosaccharidosis Lysosomal storage disease with skeletal involvement

Fucosidosis is an autosomal recessive lysosomal storage disorder caused by biallelic pathogenic variants in FUCA1, which encodes alpha-L-fucosidase. Loss of this lysosomal hydrolase impairs degradation of fucose-containing glycoproteins, glycolipids, and oligosaccharides, causing lysosomal storage in neural and visceral tissues. The disorder usually begins in infancy or childhood with developmental delay or regression, severe intellectual disability, coarse facial features, dysostosis multiplex, hepatomegaly, hyperhidrosis, skin and vascular abnormalities, hearing impairment, spasticity, seizures, and progressive neurologic deterioration.

Ask OpenScientist

Ask a research question about Fucosidosis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
1
Inheritance
9
Pathophys.
32
Phenotypes
47
Pathograph
1
Genes
3
Treatments
2
Subtypes
9
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0009254 fucosidosis
skos:exactMatch Orphanet ORPHA:349
Orphanet ORPHA:349 lists MONDO:0009254 as an exact cross-reference for fucosidosis.
📘

Definitions

1
Orphanet fucosidosis definition
A lysosomal storage disease characterized by tissue buildup of fucose-rich glycolipids and oligosaccharides with intellectual disability, developmental delay or psychomotor regression, skeletal disease, visceromegaly, hyperhidrosis, and dermatologic abnormalities.
OTHER
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"widespread tissue buildup of glycolipids and oligosaccharides rich in fucose"
Orphanet defines fucosidosis by storage of fucose-rich glycolipids and oligosaccharides.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Fucosidosis is inherited in an autosomal recessive pattern.
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:349 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance for fucosidosis.
PMID:33266441 SUPPORT Human Clinical
"Fucosidosis is inherited in an autosomal recessive manner"
The clinical review explicitly describes autosomal recessive inheritance.
◆

Subtypes

2
Type I fucosidosis
Rapidly progressive neurodegenerative fucosidosis, typically leading to decerebration and death before age 10 years.
Show evidence (1 reference)
PMID:33266441 SUPPORT Human Clinical
"Type I: a rapidly-progressing neurodegenerative course"
The clinical review defines Type I fucosidosis as a rapidly progressive neurodegenerative subtype.
Type II fucosidosis
Milder fucosidosis with slower neurologic progression, possible survival into adulthood, and frequent angiokeratoma corporis diffusum.
Show evidence (1 reference)
PMID:33266441 SUPPORT Human Clinical
"Type II: a milder course, with slower neurological symptoms progression"
The clinical review defines Type II fucosidosis as a milder, slower-progressing subtype.
⚙

Pathophysiology

9
FUCA1 alpha-L-fucosidase deficiency
Biallelic pathogenic FUCA1 variants reduce or abolish lysosomal alpha-L-fucosidase activity.
FUCA1 link
alpha-L-fucosidase activity link ↓ DECREASED
lysosome link
Downstream
Alpha-L-fucosidase activity FUCA1 pathogenic variants reduce measured alpha-L-fucosidase enzyme activity.
Fucose-rich glycoconjugate lysosomal storage Enzyme deficiency impairs degradation of fucosylated glycoconjugates.
Show evidence (2 references)
PMID:1873910 SUPPORT In Vitro
"negligible catalytic activity as compared with the mean of 19 control cultures."
Patient lymphoid cell studies directly support alpha-L-fucosidase deficiency.
PMID:39796208 SUPPORT Other
"reduced enzyme activity or complete loss of function"
The recent review summarizes the causal FUCA1-to-enzyme-deficiency relationship.
Fucose-rich glycoconjugate lysosomal storage
Impaired alpha-L-fucosidase function causes accumulation of fucose-rich oligosaccharides, glycoproteins, and glycolipids within lysosomes and in urine.
glycoprotein catabolic process link ↓ DECREASED glycosphingolipid catabolic process link ↓ DECREASED
lysosome link
Downstream
Neural lysosomal expansion and secondary storage Storage distends lysosomes and produces secondary lipid storage in the CNS.
Visceral and cutaneous storage disease Storage in liver, skin, and other tissues contributes to visceral and dermatologic manifestations.
Urinary fucose-rich oligosaccharides and glycopeptides Accumulated fucosylated glycopeptides and oligosaccharides are excessively excreted in urine.
Respiratory mucus clearance impairment Altered handling of fucose-containing airway glycoconjugates is suspected to impair mucus clearance.
Skeletal dysostosis involvement Lysosomal storage disease is associated with dysostosis multiplex and vertebral skeletal abnormalities through incompletely defined intermediates.
Ocular storage involvement Fucosidosis can include conjunctival, retinal, and corneal storage-related ocular involvement.
Brachycephaly The multisystem developmental presentation of fucosidosis includes brachycephaly through incompletely defined intermediates.
Coarse facial features The multisystem lysosomal storage phenotype includes coarse facial features through incompletely defined craniofacial intermediates.
Abnormal facial shape The multisystem developmental presentation of fucosidosis includes facial dysmorphism through incompletely defined intermediates.
Prominent forehead The multisystem craniofacial presentation of fucosidosis includes prominent forehead through incompletely defined intermediates.
Failure to thrive The severe multisystem storage phenotype is associated with growth failure through incompletely defined intermediates.
Mucopolysacchariduria Abnormal urinary storage products are associated with a mucopolysacchariduria-like biochemical phenotype.
Lipoatrophy The multisystem storage phenotype includes lipoatrophy through incompletely defined intermediates.
Abnormality of the cardiovascular system The multisystem storage phenotype can include cardiovascular abnormalities through incompletely defined intermediates.
Abnormality of the gallbladder The multisystem storage phenotype can include gallbladder abnormalities through incompletely defined intermediates.
Hypothyroidism The multisystem storage phenotype includes hypothyroidism through incompletely defined endocrine intermediates.
Abnormality of the dentition The multisystem developmental phenotype includes dental abnormalities through incompletely defined intermediates.
Cardiomegaly The multisystem storage phenotype can include cardiomegaly through incompletely defined cardiovascular intermediates.
Show evidence (2 references)
ORPHA:349 SUPPORT Other
"widespread tissue buildup of glycolipids and oligosaccharides rich in fucose"
Orphanet directly supports fucose-rich substrate storage.
PMID:33266441 SUPPORT Human Clinical
"accumulation of fucose-containing glycolipids and glycoproteins in various tissues and urine"
The clinical review links hydrolase deficiency to storage of fucose-containing substrates.
Neural lysosomal expansion and secondary storage
Fucosylated substrate storage expands lysosomal compartments in CNS cells, produces secondary storage material, and injures vulnerable neurons.
neuron link oligodendrocyte link
brain link
Downstream
Neuroinflammation and neural cell loss Expanded lysosomal storage is associated with inflammatory gliosis and neuronal loss.
Hypomyelination CNS storage disease is associated with oligodendrocyte loss and hypomyelination.
Show evidence (2 references)
PMID:27491075 SUPPORT Model Organism
"Lysosomal storage pathology was observed in many visceral"
The Fuca1 knockout mouse model supports lysosomal storage pathology across tissues.
PMID:27491075 SUPPORT Model Organism
"lysosomal compartment in various cell types"
The model directly shows expanded lysosomal compartments in the CNS.
Neuroinflammation and neural cell loss
CNS storage pathology activates inflammatory glia and is accompanied by apoptosis, axonal injury, and loss of vulnerable neurons.
microglial cell link astrocyte link neuron link
inflammatory response link ↑ INCREASED apoptotic process link ↑ INCREASED
Downstream
Severe intellectual disability Neuronal injury and neuroinflammation contribute to severe cognitive impairment.
Global developmental delay CNS storage pathology and neurodegeneration are associated with developmental delay and psychomotor decline.
Seizure Neural injury and inflammation contribute to epilepsy susceptibility.
Spasticity CNS injury contributes to progressive pyramidal and motor dysfunction.
Hypotonia CNS storage pathology and motor deterioration are associated with hypotonia through incompletely defined intermediates.
Decreased muscle mass Progressive neurologic and multisystem disease is associated with decreased muscle mass through incompletely defined intermediates.
Show evidence (2 references)
PMID:27491075 SUPPORT Model Organism
"neuroinflammation, as well as a progressive loss of Purkinje cells"
The Fuca1 knockout mouse demonstrates neuroinflammation, astrogliosis, and neuronal loss.
PMID:39796208 SUPPORT Other
"neuronal loss, leading to the neurodegenerative symptoms of fucosidosis."
The review summarizes CNS lysosomal dysfunction leading to inflammation and neuronal loss.
Hypomyelination
CNS fucosidosis storage pathology includes oligodendrocyte loss and reduced myelination, supporting white-matter disease and progressive motor impairment.
oligodendrocyte link
myelination link ↓ DECREASED
brain white matter link
Downstream
Spastic tetraplegia White-matter disease contributes to progressive motor impairment.
Hearing impairment CNS white-matter involvement can coincide with auditory pathway abnormalities and hearing impairment, but the causal intermediate is incompletely defined.
Abnormal pyramidal sign White-matter and corticospinal motor involvement can produce pyramidal signs through incompletely defined intermediates.
Show evidence (2 references)
PMID:26537923 SUPPORT Model Organism
"oligodendrocyte loss, and hypomyelination throughout the"
The canine fucosidosis model shows oligodendrocyte loss and hypomyelination.
PMID:11360116 SUPPORT Human Clinical
"MRI showed diffuse hypomyelination"
A human pre-transplant evaluation documented diffuse hypomyelination.
Visceral and cutaneous storage disease
Fucose-rich substrate storage in visceral and skin tissues is associated with hepatomegaly, hyperhidrosis, angiokeratoma or telangiectatic vascular skin abnormalities, hyperkeratosis, and other extracerebral features.
keratinocyte link
liver link skin of body link
Downstream
Hepatomegaly Visceral storage contributes to liver enlargement.
Hyperhidrosis Cutaneous involvement contributes to abnormal sweating.
Generalized hyperkeratosis Cutaneous storage disease is associated with generalized hyperkeratosis through incompletely defined intermediates.
Vascular skin abnormality Skin involvement includes telangiectasia and angiokeratoma.
Acrocyanosis Cutaneous vascular involvement can include acrocyanosis through incompletely defined intermediates.
Abnormal nail morphology Cutaneous involvement can include distal nail changes through incompletely defined intermediates.
Show evidence (2 references)
PMID:33266441 SUPPORT Human Clinical
"accretion of fucose-containing oligosaccharides, glycoproteins, and glycolipids in the brain, liver and skin"
The review explicitly places storage material in brain, liver, and skin.
PMID:33266441 SUPPORT Human Clinical
"skin abnormalities also include widespread telangiectasia, skin thickness, hyperhidrosis"
The clinical review supports cutaneous disease as part of fucosidosis.
Respiratory mucus clearance impairment
Fucosidosis respiratory infections may reflect local airway mucus-clearance vulnerability. The clinical review notes intact immune testing in reported patients and proposes altered fucose/sialic-acid-dependent mucus cross-linking and viscoelasticity as a contributor.
mucociliary clearance link ↓ DECREASED
Downstream
Recurrent respiratory infections Impaired local mucus clearance is suspected to increase recurrent respiratory infections.
Show evidence (2 references)
PMID:33266441 PARTIAL Human Clinical
"it was suspected that there could be a local defect in mucus clearance."
The review proposes impaired mucus clearance as a contributor to recurrent respiratory infections.
PMID:33266441 PARTIAL Human Clinical
"terminal sugars fucose and sialic acid play a major role in defining the viscoelasticity of mucus."
The review gives the proposed glycoconjugate-mucus intermediate.
Skeletal dysostosis involvement
Fucosidosis includes skeletal involvement with dysostosis multiplex and vertebral changes. The direct cellular intermediates between fucose-rich storage and skeletal morphology are not specified in the cached evidence.
Downstream
Dysostosis multiplex Skeletal involvement manifests as dysostosis multiplex.
Anterior beaking of lumbar vertebrae Vertebral skeletal involvement includes anterior tonguing or beaking.
Kyphosis Skeletal involvement can include kyphotic/gibbous spinal deformity.
Show evidence (2 references)
ORPHA:349 SUPPORT Other
"developmental delay associated with psychomotor regression and bone abnormalities"
Orphanet definition supports skeletal/bone involvement in fucosidosis.
PMID:33266441 SUPPORT Human Clinical
"Some patients also have non-specific features of dysostosis multiplex"
The clinical review supports dysostosis multiplex as a skeletal manifestation.
Ocular storage involvement
Fucosidosis can involve ocular tissues, including conjunctival and retinal vessels and corneal clarity. The cached clinical review links storage material to ocular vessels and lists corneal opacities in affected patients.
eye link
Downstream
Corneal opacity Ocular storage involvement can include corneal opacity.
Show evidence (2 references)
PMID:33266441 SUPPORT Human Clinical
"storage material accumulates in conjunctival, retinal, and skin vessels."
The clinical review supports ocular vessel storage involvement.
PMID:33266441 SUPPORT Human Clinical
"corneal opacities in 11%"
The clinical review documents corneal opacity in patients.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Fucosidosis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

32
Cardiovascular 2
Abnormality of the cardiovascular system FREQUENT Abnormality of the cardiovascular system (HP:0001626)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0001626 | Abnormality of the cardiovascular system | Frequent (79-30%)"
Orphanet lists cardiovascular abnormality as frequent.
Cardiomegaly OCCASIONAL Cardiomegaly (HP:0001640)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0001640 | Cardiomegaly | Occasional (29-5%)"
Orphanet lists cardiomegaly as occasional.
Digestive 1
Hepatomegaly VERY_FREQUENT Hepatomegaly (HP:0002240)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0002240 | Hepatomegaly | Very frequent (99-80%)"
Orphanet lists hepatomegaly as very frequent.
Ear 1
Hearing impairment VERY_FREQUENT Hearing impairment (HP:0000365)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0000365 | Hearing impairment | Very frequent (99-80%)"
Orphanet lists hearing impairment as very frequent.
Endocrine 1
Hypothyroidism VERY_FREQUENT Hypothyroidism (HP:0000821)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0000821 | Hypothyroidism | Very frequent (99-80%)"
Orphanet lists hypothyroidism as very frequent.
Eye 1
Corneal opacity FREQUENT Corneal opacity (HP:0007957)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0007957 | Corneal opacity | Frequent (79-30%)"
Orphanet lists corneal opacity as frequent.
Head and Neck 5
Brachycephaly VERY_FREQUENT Brachycephaly (HP:0000248)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0000248 | Brachycephaly | Very frequent (99-80%)"
Orphanet lists brachycephaly as very frequent.
Coarse facial features VERY_FREQUENT Coarse facial features (HP:0000280)
Show evidence (2 references)
ORPHA:349 SUPPORT Other
"HP:0000280 | Coarse facial features | Very frequent (99-80%)"
Orphanet lists coarse facial features as very frequent.
PMID:33266441 SUPPORT Human Clinical
"Clinical features include coarse facial features"
The clinical review lists coarse facial features among the manifestations.
Abnormal facial shape VERY_FREQUENT Abnormal facial shape (HP:0001999)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0001999 | Abnormal facial shape | Very frequent (99-80%)"
Orphanet lists abnormal facial shape as very frequent.
Prominent forehead VERY_FREQUENT Prominent forehead (HP:0011220)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0011220 | Prominent forehead | Very frequent (99-80%)"
Orphanet lists prominent forehead as very frequent.
Abnormality of the dentition OCCASIONAL Abnormality of the dentition (HP:0000164)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0000164 | Abnormality of the dentition | Occasional (29-5%)"
Orphanet lists dentition abnormality as occasional.
Immune 1
Recurrent respiratory infections FREQUENT Recurrent respiratory infections (HP:0002205)
Show evidence (2 references)
PMID:33266441 SUPPORT Human Clinical
"Up to 78% of patients experience respiratory tract infections"
The clinical review supports recurrent respiratory infections as a frequent fucosidosis phenotype.
PMID:33266441 SUPPORT Human Clinical
"around 60% of patients die secondary to respiratory infections and neurological deteriorations"
The same review supports respiratory infections as clinically important contributors to fucosidosis mortality.
Integument 3
Hyperhidrosis VERY_FREQUENT Hyperhidrosis (HP:0000975)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0000975 | Hyperhidrosis | Very frequent (99-80%)"
Orphanet lists hyperhidrosis as very frequent.
Acrocyanosis OCCASIONAL Acrocyanosis (HP:0001063)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0001063 | Acrocyanosis | Occasional (29-5%)"
Orphanet lists acrocyanosis as occasional.
Abnormal nail morphology OCCASIONAL Abnormal nail morphology (HP:0001597)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0001597 | Abnormality of the nail | Occasional (29-5%)"
Orphanet lists nail abnormality as occasional.
Musculoskeletal 4
Dysostosis multiplex VERY_FREQUENT Dysostosis multiplex (HP:0000943)
Show evidence (2 references)
ORPHA:349 SUPPORT Other
"HP:0000943 | Dysostosis multiplex | Very frequent (99-80%)"
Orphanet lists dysostosis multiplex as very frequent.
PMID:33266441 SUPPORT Human Clinical
"dysostosis multiplex, and angiokeratoma corporis"
The clinical review lists dysostosis multiplex among major features.
Kyphosis VERY_FREQUENT Kyphosis (HP:0002808)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0002808 | Kyphosis | Very frequent (99-80%)"
Orphanet lists kyphosis as very frequent.
Hypotonia FREQUENT Hypotonia (HP:0001252)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0001252 | Hypotonia | Frequent (79-30%)"
Orphanet lists hypotonia as frequent.
Spasticity FREQUENT Spasticity (HP:0001257)
Show evidence (2 references)
ORPHA:349 SUPPORT Other
"HP:0001257 | Spasticity | Frequent (79-30%)"
Orphanet lists spasticity as frequent.
PMID:33266441 SUPPORT Human Clinical
"estimated to affect up to 40% of all fucosidosis cases"
The review supports spasticity within the frequent band.
Nervous System 3
Severe intellectual disability VERY_FREQUENT Severe intellectual disability (HP:0010864)
Show evidence (2 references)
ORPHA:349 SUPPORT Other
"HP:0010864 | Intellectual disability, severe | Very frequent (99-80%)"
Orphanet lists severe intellectual disability as very frequent.
PMID:33266441 SUPPORT Human Clinical
"up to 95% of patients have progressive mental health deterioration"
The clinical review supports high-frequency progressive cognitive deterioration.
Global developmental delay VERY_FREQUENT Global developmental delay (HP:0001263)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0001263 | Global developmental delay | Very frequent (99-80%)"
Orphanet lists global developmental delay as very frequent.
Seizure FREQUENT Seizure (HP:0001250)
Show evidence (2 references)
ORPHA:349 SUPPORT Other
"HP:0001250 | Seizure | Frequent (79-30%)"
Orphanet lists seizures as frequent.
PMID:33266441 SUPPORT Human Clinical
"seizures may occur in 38% of patients"
The clinical review provides quantitative support for the frequent band.
Growth 1
Failure to thrive VERY_FREQUENT Failure to thrive (HP:0001508)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0001508 | Failure to thrive | Very frequent (99-80%)"
Orphanet lists failure to thrive as very frequent.
Other 9
Anterior beaking of lumbar vertebrae VERY_FREQUENT Anterior beaking of lumbar vertebrae (HP:0008430)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0008430 | Anterior beaking of lumbar vertebrae | Very frequent (99-80%)"
Orphanet lists anterior beaking of lumbar vertebrae as very frequent.
Generalized hyperkeratosis VERY_FREQUENT Generalized hyperkeratosis (HP:0005595)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0005595 | Generalized hyperkeratosis | Very frequent (99-80%)"
Orphanet lists generalized hyperkeratosis as very frequent.
Mucopolysacchariduria VERY_FREQUENT Mucopolysacchariduria (HP:0008155)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0008155 | Mucopolysacchariduria | Very frequent (99-80%)"
Orphanet lists mucopolysacchariduria as very frequent.
Lipoatrophy VERY_FREQUENT Lipoatrophy (HP:0100578)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0100578 | Lipoatrophy | Very frequent (99-80%)"
Orphanet lists lipoatrophy as very frequent.
Spastic tetraplegia FREQUENT Spastic tetraplegia (HP:0002510)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0002510 | Spastic tetraplegia | Frequent (79-30%)"
Orphanet lists spastic tetraplegia as frequent.
Decreased muscle mass FREQUENT Decreased muscle mass (HP:0003199)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0003199 | Decreased muscle mass | Frequent (79-30%)"
Orphanet lists decreased muscle mass as frequent.
Abnormality of the gallbladder FREQUENT Abnormality of the gallbladder (HP:0005264)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0005264 | Abnormality of the gallbladder | Frequent (79-30%)"
Orphanet lists gallbladder abnormality as frequent.
Vascular skin abnormality FREQUENT Vascular skin abnormality (HP:0011276)
Show evidence (2 references)
ORPHA:349 SUPPORT Other
"HP:0011276 | Vascular skin abnormality | Frequent (79-30%)"
Orphanet lists vascular skin abnormality as frequent.
PMID:38053939 SUPPORT Human Clinical
"angiokeratomas with differing severity."
Adult sibling follow-up documents angiokeratomas as typical fucosidosis features.
Abnormal pyramidal sign OCCASIONAL Abnormal pyramidal sign (HP:0007256)
Show evidence (1 reference)
ORPHA:349 SUPPORT Other
"HP:0007256 | Abnormal pyramidal sign | Occasional (29-5%)"
Orphanet lists abnormal pyramidal sign as occasional.
🧬

Genetic Associations

1
FUCA1 (Causal loss-of-function variant)
Show evidence (3 references)
ORPHA:349 SUPPORT Other
"FUCA1 | alpha-L-fucosidase 1 | hgnc:4006 | Disease-causing germline mutation(s) in"
Orphanet asserts FUCA1 germline mutations as disease-causing.
PMID:33266441 SUPPORT Human Clinical
"Fucosidosis is caused by mutations in the FUCA1 gene resulting in"
The clinical review identifies FUCA1 mutations as causal.
CGGV:assertion_e88e0ef6-e788-40e2-bbd4-7fb3efb6b0ea-2022-08-02T160000.000Z SUPPORT Other
"FUCA1 | HGNC:4006 | fucosidosis | MONDO:0009254 | AR | Definitive"
ClinGen classifies the FUCA1-fucosidosis gene-disease relationship as definitive with autosomal recessive inheritance.
💊

Treatments

3
Supportive care
Action: supportive care MAXO:0000950
Supportive multidisciplinary management addresses motor impairment, feeding, orthopedic, ophthalmologic, cardiologic, neurologic, neuropsychiatric, and developmental complications.
Target Phenotypes: Spasticity ↗
Show evidence (2 references)
PMID:33266441 SUPPORT Human Clinical
"The cornerstone of management is generally supportive"
The clinical review identifies supportive multidisciplinary care as the management cornerstone.
PMID:27491218 SUPPORT Other
"supportive care are limited."
The therapy review supports supportive care as the main non-targeted management option.
Hematopoietic stem cell transplantation
Action: hematopoietic stem cell transplantation MAXO:0000747
Hematopoietic stem cell transplantation has been used in a small number of carefully selected patients and may delay disease progression when performed early, but risks and exclusion criteria limit use.
Mechanism Target:
RESTORES FUCA1 alpha-L-fucosidase deficiency — Donor-derived hematopoietic cells can provide enzyme cross-correction.
Show evidence (1 reference)
PMID:11360116 SUPPORT Human Clinical
"Follow-up showed a progressive rise of enzymatic levels."
Post-transplant follow-up showed rising alpha-L-fucosidase enzyme levels.
Target Phenotypes: Global developmental delay ↗ Hearing impairment ↗
Show evidence (2 references)
PMID:11360116 SUPPORT Human Clinical
"improved, as confirmed by evaluation of evoked potentials and by MRI scanning."
The reported child had improved psychomotor development after unrelated donor bone marrow transplantation.
PMID:27491218 SUPPORT Other
"delaying the disease course."
The therapy review frames hematopoietic transplant as the available disease-course-delaying option.
Intracisternal enzyme replacement therapy
Action: Pharmacotherapy NCIT:C15986
Intracisternal enzyme replacement is preclinical and has reduced neuropathology in canine fucosidosis models, but more complete and sustained correction is needed before it can be considered an established human treatment.
Mechanism Target:
RESTORES FUCA1 alpha-L-fucosidase deficiency — Recombinant alpha-L-fucosidase aims to replace deficient enzyme activity in the CNS.
Show evidence (1 reference)
PMID:26537923 PARTIAL Model Organism
"recombinant canine α-L-fucosidase delivered"
The canine study tested CNS delivery of recombinant alpha-L-fucosidase.
Show evidence (1 reference)
PMID:26537923 PARTIAL Model Organism
"reduced severity of fucosidosis neuropathology with partial"
The canine model supports partial preclinical benefit, not an established human therapy.
🔬

Biochemical Markers

2
Alpha-L-fucosidase activity (Reduced)
Context: Diagnostic enzyme assay
Pathograph Readouts
Readout Of FUCA1 alpha-L-fucosidase deficiency Negative Diagnostic
Reduced alpha-L-fucosidase activity directly reports the primary FUCA1 lysosomal hydrolase deficiency.
Show evidence (1 reference)
PMID:1873910 SUPPORT In Vitro
"negligible catalytic activity as compared with the mean of 19 control cultures."
Patient lymphoid-cell assays directly support low alpha-L-fucosidase catalytic activity as a readout of the root enzyme deficiency.
Show evidence (1 reference)
PMID:1873910 SUPPORT In Vitro
"16-fold lower extracellular alpha-L-fucosidase"
Patient lymphoid cells showed markedly reduced enzyme protein.
Urinary fucose-rich oligosaccharides and glycopeptides (Elevated)
Context: Biochemical storage marker
Pathograph Readouts
Readout Of Fucose-rich glycoconjugate lysosomal storage Positive Diagnostic
Increased urinary fucose-rich oligosaccharides and glycopeptides report the fucosylated glycoconjugate storage burden caused by alpha-L-fucosidase deficiency.
Show evidence (1 reference)
PMID:33266441 SUPPORT Human Clinical
"Patients affected with fucosidosis excrete a large amount of glycopeptide in the urine"
The review supports urinary fucosylated glycopeptide excretion as a diagnostic readout of fucose-rich glycoconjugate storage.
Show evidence (1 reference)
PMID:33266441 SUPPORT Human Clinical
"Patients affected with fucosidosis excrete a large amount of glycopeptide in the urine"
The review supports urinary excretion of abnormal fucosylated storage products.
{ }

Source YAML

click to show 
name: Fucosidosis
category: Mendelian
creation_date: "2026-05-04T15:41:26Z"
updated_date: "2026-05-21T07:31:07Z"
synonyms:
- Alpha-L-fucosidase deficiency
description: >
  Fucosidosis is an autosomal recessive lysosomal storage disorder caused by
  biallelic pathogenic variants in FUCA1, which encodes alpha-L-fucosidase.
  Loss of this lysosomal hydrolase impairs degradation of fucose-containing
  glycoproteins, glycolipids, and oligosaccharides, causing lysosomal storage in
  neural and visceral tissues. The disorder usually begins in infancy or
  childhood with developmental delay or regression, severe intellectual
  disability, coarse facial features, dysostosis multiplex, hepatomegaly,
  hyperhidrosis, skin and vascular abnormalities, hearing impairment, spasticity,
  seizures, and progressive neurologic deterioration.
disease_term:
  preferred_term: fucosidosis
  term:
    id: MONDO:0009254
    label: fucosidosis
parents:
- Oligosaccharidosis
- Lysosomal storage disease with skeletal involvement
has_subtypes:
- name: Type I
  display_name: Type I fucosidosis
  description: >
    Rapidly progressive neurodegenerative fucosidosis, typically leading to
    decerebration and death before age 10 years.
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type I: a rapidly-progressing neurodegenerative course"
    explanation: The clinical review defines Type I fucosidosis as a rapidly progressive neurodegenerative subtype.
- name: Type II
  display_name: Type II fucosidosis
  description: >
    Milder fucosidosis with slower neurologic progression, possible survival
    into adulthood, and frequent angiokeratoma corporis diffusum.
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type II: a milder course, with slower neurological symptoms progression"
    explanation: The clinical review defines Type II fucosidosis as a milder, slower-progressing subtype.
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0009254
      label: fucosidosis
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:349
    mapping_justification: >
      Orphanet ORPHA:349 lists MONDO:0009254 as an exact cross-reference for
      fucosidosis.
external_assertions:
- name: Orphanet fucosidosis record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:349
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=349
  description: >
    Orphanet's ORPHA:349 structured record for fucosidosis includes the exact
    MONDO and OMIM cross-references, autosomal recessive inheritance, FUCA1
    disease-gene assertion, definition, epidemiology, and HPO phenotype rows
    used in this entry.
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0009254 | Exact"
    explanation: Orphanet maps ORPHA:349 exactly to the MONDO identifier used by this entry.
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:230000 | Exact"
    explanation: Orphanet lists OMIM:230000 as an exact external cross-reference.
definitions:
- name: Orphanet fucosidosis definition
  definition_type: OTHER
  description: >
    A lysosomal storage disease characterized by tissue buildup of
    fucose-rich glycolipids and oligosaccharides with intellectual disability,
    developmental delay or psychomotor regression, skeletal disease,
    visceromegaly, hyperhidrosis, and dermatologic abnormalities.
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "widespread tissue buildup of glycolipids and oligosaccharides rich in fucose"
    explanation: Orphanet defines fucosidosis by storage of fucose-rich glycolipids and oligosaccharides.
inheritance:
- name: Autosomal recessive inheritance
  description: Fucosidosis is inherited in an autosomal recessive pattern.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance for fucosidosis.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fucosidosis is inherited in an autosomal recessive manner"
    explanation: The clinical review explicitly describes autosomal recessive inheritance.
prevalence:
- population: Worldwide
  percentage: Ultra-rare
  notes: >
    Fucosidosis is very rare, with Orphanet listing a worldwide point prevalence
    below 1 per 1,000,000 and published reviews summarizing approximately 120
    reported cases.
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<1 / 1 000 000 | Worldwide | Point prevalence"
    explanation: Orphanet's epidemiology table supports ultra-rare worldwide prevalence.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "So far approximately 120 cases have been described"
    explanation: The review's case count supports the ultra-rare prevalence framing.
progression:
- phase: Infantile or childhood onset
  age_range: Infancy to childhood
  notes: >
    Presentation typically begins in infancy or childhood with developmental
    delay, psychomotor regression, coarse features, skeletal disease, and
    visceral or skin involvement.
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Infancy"
    explanation: Orphanet records infancy as an age of onset.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean age at presentation of the first symptom in 60 patients was 1.2"
    explanation: The clinical review supports early childhood presentation.
- phase: Progressive neurologic deterioration
  age_range: Childhood onward
  notes: >
    Neurologic disease progresses variably; severe cases can lose motor and
    language milestones early, while milder cases may retain some function into
    adolescence or adulthood.
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type I: a rapidly-progressing neurodegenerative course"
    explanation: The review summarizes the rapid neurodegenerative course of severe fucosidosis.
  - reference: PMID:38053939
    reference_title: Long-term outcomes in two adult siblings with Fucosidosis - Diagnostic odyssey and clinical manifestations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "have slow neurologic deterioration."
    explanation: Adult sibling follow-up supports the broader spectrum of slower neurologic deterioration.
genetic:
- name: FUCA1
  association: Causal loss-of-function variant
  gene_term:
    preferred_term: FUCA1
    term:
      id: hgnc:4006
      label: FUCA1
  variant_origin: GERMLINE
  notes: >
    Biallelic pathogenic FUCA1 variants cause fucosidosis by reducing or
    abolishing alpha-L-fucosidase protein function and activity.
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FUCA1 | alpha-L-fucosidase 1 | hgnc:4006 | Disease-causing germline mutation(s) in"
    explanation: Orphanet asserts FUCA1 germline mutations as disease-causing.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fucosidosis is caused by mutations in the FUCA1 gene resulting in"
    explanation: The clinical review identifies FUCA1 mutations as causal.
  - reference: CGGV:assertion_e88e0ef6-e788-40e2-bbd4-7fb3efb6b0ea-2022-08-02T160000.000Z
    reference_title: "FUCA1 / fucosidosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FUCA1 | HGNC:4006 | fucosidosis | MONDO:0009254 | AR | Definitive"
    explanation: ClinGen classifies the FUCA1-fucosidosis gene-disease relationship as definitive with autosomal recessive inheritance.
pathophysiology:
- name: FUCA1 alpha-L-fucosidase deficiency
  description: >
    Biallelic pathogenic FUCA1 variants reduce or abolish lysosomal
    alpha-L-fucosidase activity.
  genes:
  - preferred_term: FUCA1
    term:
      id: hgnc:4006
      label: FUCA1
  molecular_functions:
  - preferred_term: alpha-L-fucosidase activity
    modifier: DECREASED
    term:
      id: GO:0004560
      label: alpha-L-fucosidase activity
  locations:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:1873910
    reference_title: Defective expression of alpha-L-fucosidase by lymphoid cells of a fucosidosis patient.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "negligible catalytic activity as compared with the mean of 19 control cultures."
    explanation: Patient lymphoid cell studies directly support alpha-L-fucosidase deficiency.
  - reference: PMID:39796208
    reference_title: "Fucosidosis: A Review of a Rare Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "reduced enzyme activity or complete loss of function"
    explanation: The recent review summarizes the causal FUCA1-to-enzyme-deficiency relationship.
  downstream:
  - target: Alpha-L-fucosidase activity
    description: FUCA1 pathogenic variants reduce measured alpha-L-fucosidase enzyme activity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:1873910
      reference_title: Defective expression of alpha-L-fucosidase by lymphoid cells of a fucosidosis patient.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "negligible catalytic activity as compared with the mean of 19 control cultures."
      explanation: Patient-derived lymphoid cells directly showed negligible alpha-L-fucosidase catalytic activity.
  - target: Fucose-rich glycoconjugate lysosomal storage
    description: Enzyme deficiency impairs degradation of fucosylated glycoconjugates.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "incomplete catabolism of N- and O-glycosylproteins results in the accumulation of fucose-containing glycolipids and glycoproteins in various tissues and urine"
      explanation: Human clinical review evidence directly links alpha-L-fucosidase deficiency to fucosylated substrate accumulation.
- name: Fucose-rich glycoconjugate lysosomal storage
  description: >
    Impaired alpha-L-fucosidase function causes accumulation of fucose-rich
    oligosaccharides, glycoproteins, and glycolipids within lysosomes and in
    urine.
  chemical_entities:
  - preferred_term: fucose
    modifier: INCREASED
    term:
      id: CHEBI:33984
      label: fucose
  - preferred_term: oligosaccharide
    modifier: INCREASED
    term:
      id: CHEBI:50699
      label: oligosaccharide
  - preferred_term: glycolipid
    modifier: INCREASED
    term:
      id: CHEBI:33563
      label: glycolipid
  biological_processes:
  - preferred_term: glycoprotein catabolic process
    modifier: DECREASED
    term:
      id: GO:0006516
      label: glycoprotein catabolic process
  - preferred_term: glycosphingolipid catabolic process
    modifier: DECREASED
    term:
      id: GO:0046479
      label: glycosphingolipid catabolic process
  locations:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "widespread tissue buildup of glycolipids and oligosaccharides rich in fucose"
    explanation: Orphanet directly supports fucose-rich substrate storage.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "accumulation of fucose-containing glycolipids and glycoproteins in various tissues and urine"
    explanation: The clinical review links hydrolase deficiency to storage of fucose-containing substrates.
  downstream:
  - target: Neural lysosomal expansion and secondary storage
    description: Storage distends lysosomes and produces secondary lipid storage in the CNS.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27491075
      reference_title: A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In the CNS, cellular alterations included enlargement of the"
      explanation: The Fuca1 knockout mouse demonstrates lysosomal storage pathology in visceral organs and the CNS.
  - target: Visceral and cutaneous storage disease
    description: Storage in liver, skin, and other tissues contributes to visceral and dermatologic manifestations.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "accretion of fucose-containing oligosaccharides, glycoproteins, and glycolipids in the brain, liver and skin"
      explanation: Human clinical review evidence places fucose-containing storage material in liver and skin.
  - target: Urinary fucose-rich oligosaccharides and glycopeptides
    description: Accumulated fucosylated glycopeptides and oligosaccharides are excessively excreted in urine.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients affected with fucosidosis excrete a large amount of glycopeptide in the urine"
      explanation: The clinical review directly supports urinary excretion of fucosylated storage products.
  - target: Respiratory mucus clearance impairment
    description: Altered handling of fucose-containing airway glycoconjugates is suspected to impair mucus clearance.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Altered terminal sugar cleavage affecting mucus cross-linking and viscoelasticity.
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "it was suspected that there could be a local defect in mucus clearance."
      explanation: The review reports a suspected local mucus-clearance defect in fucosidosis respiratory disease.
  - target: Skeletal dysostosis involvement
    description: Lysosomal storage disease is associated with dysostosis multiplex and vertebral skeletal abnormalities through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Some patients also have non-specific features of dysostosis multiplex"
      explanation: The clinical review supports skeletal dysostosis as part of fucosidosis.
  - target: Ocular storage involvement
    description: Fucosidosis can include conjunctival, retinal, and corneal storage-related ocular involvement.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Storage material in conjunctival and retinal vessels with corneal involvement.
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "storage material accumulates in conjunctival, retinal, and skin vessels."
      explanation: The clinical review directly supports ocular vascular storage involvement.
  - target: Brachycephaly
    description: The multisystem developmental presentation of fucosidosis includes brachycephaly through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000248 | Brachycephaly | Very frequent (99-80%)"
      explanation: Orphanet records brachycephaly as a very frequent fucosidosis phenotype.
  - target: Coarse facial features
    description: The multisystem lysosomal storage phenotype includes coarse facial features through incompletely defined craniofacial intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Clinical features include coarse facial features"
      explanation: The clinical review lists coarse facial features among fucosidosis manifestations.
  - target: Abnormal facial shape
    description: The multisystem developmental presentation of fucosidosis includes facial dysmorphism through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001999 | Abnormal facial shape | Very frequent (99-80%)"
      explanation: Orphanet records abnormal facial shape as a very frequent fucosidosis phenotype.
  - target: Prominent forehead
    description: The multisystem craniofacial presentation of fucosidosis includes prominent forehead through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0011220 | Prominent forehead | Very frequent (99-80%)"
      explanation: Orphanet records prominent forehead as a very frequent fucosidosis phenotype.
  - target: Failure to thrive
    description: The severe multisystem storage phenotype is associated with growth failure through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the weight of 77% was below the fifth centile."
      explanation: The clinical review supports growth and weight failure in fucosidosis.
  - target: Mucopolysacchariduria
    description: Abnormal urinary storage products are associated with a mucopolysacchariduria-like biochemical phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0008155 | Mucopolysacchariduria | Very frequent (99-80%)"
      explanation: Orphanet records mucopolysacchariduria as a very frequent biochemical phenotype.
  - target: Lipoatrophy
    description: The multisystem storage phenotype includes lipoatrophy through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0100578 | Lipoatrophy | Very frequent (99-80%)"
      explanation: Orphanet records lipoatrophy as a very frequent fucosidosis phenotype.
  - target: Abnormality of the cardiovascular system
    description: The multisystem storage phenotype can include cardiovascular abnormalities through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001626 | Abnormality of the cardiovascular system | Frequent (79-30%)"
      explanation: Orphanet records cardiovascular abnormality as a frequent fucosidosis phenotype.
  - target: Abnormality of the gallbladder
    description: The multisystem storage phenotype can include gallbladder abnormalities through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0005264 | Abnormality of the gallbladder | Frequent (79-30%)"
      explanation: Orphanet records gallbladder abnormality as a frequent fucosidosis phenotype.
  - target: Hypothyroidism
    description: The multisystem storage phenotype includes hypothyroidism through incompletely defined endocrine intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000821 | Hypothyroidism | Very frequent (99-80%)"
      explanation: Orphanet records hypothyroidism as a very frequent fucosidosis phenotype.
  - target: Abnormality of the dentition
    description: The multisystem developmental phenotype includes dental abnormalities through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000164 | Abnormality of the dentition | Occasional (29-5%)"
      explanation: Orphanet records dentition abnormality as an occasional fucosidosis phenotype.
  - target: Cardiomegaly
    description: The multisystem storage phenotype can include cardiomegaly through incompletely defined cardiovascular intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001640 | Cardiomegaly | Occasional (29-5%)"
      explanation: Orphanet records cardiomegaly as an occasional fucosidosis phenotype.
- name: Neural lysosomal expansion and secondary storage
  description: >
    Fucosylated substrate storage expands lysosomal compartments in CNS cells,
    produces secondary storage material, and injures vulnerable neurons.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:27491075
    reference_title: A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Lysosomal storage pathology was observed in many visceral"
    explanation: The Fuca1 knockout mouse model supports lysosomal storage pathology across tissues.
  - reference: PMID:27491075
    reference_title: A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "lysosomal compartment in various cell types"
    explanation: The model directly shows expanded lysosomal compartments in the CNS.
  downstream:
  - target: Neuroinflammation and neural cell loss
    description: Expanded lysosomal storage is associated with inflammatory gliosis and neuronal loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27491075
      reference_title: A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "neuroinflammation, as well as a progressive loss of Purkinje cells"
      explanation: The Fuca1 knockout mouse links CNS lysosomal storage pathology to neuroinflammation and neuronal loss.
  - target: Hypomyelination
    description: CNS storage disease is associated with oligodendrocyte loss and hypomyelination.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Oligodendrocyte loss in CNS storage pathology.
    evidence:
    - reference: PMID:26537923
      reference_title: The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "oligodendrocyte loss, and hypomyelination throughout the"
      explanation: The canine model links fucosidosis CNS pathology to oligodendrocyte loss and hypomyelination.
- name: Neuroinflammation and neural cell loss
  description: >
    CNS storage pathology activates inflammatory glia and is accompanied by
    apoptosis, axonal injury, and loss of vulnerable neurons.
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:27491075
    reference_title: A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "neuroinflammation, as well as a progressive loss of Purkinje cells"
    explanation: The Fuca1 knockout mouse demonstrates neuroinflammation, astrogliosis, and neuronal loss.
  - reference: PMID:39796208
    reference_title: "Fucosidosis: A Review of a Rare Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "neuronal loss, leading to the neurodegenerative symptoms of fucosidosis."
    explanation: The review summarizes CNS lysosomal dysfunction leading to inflammation and neuronal loss.
  downstream:
  - target: Severe intellectual disability
    description: Neuronal injury and neuroinflammation contribute to severe cognitive impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Progressive mental deterioration and neuronal loss.
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "up to 95% of patients have progressive mental health deterioration"
      explanation: The clinical review supports severe cognitive deterioration downstream of fucosidosis neurodegeneration.
  - target: Global developmental delay
    description: CNS storage pathology and neurodegeneration are associated with developmental delay and psychomotor decline.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001263 | Global developmental delay | Very frequent (99-80%)"
      explanation: Orphanet records global developmental delay as a very frequent phenotype.
  - target: Seizure
    description: Neural injury and inflammation contribute to epilepsy susceptibility.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "seizures may occur in 38% of patients"
      explanation: The clinical review supports seizures as a frequent neurologic manifestation.
  - target: Spasticity
    description: CNS injury contributes to progressive pyramidal and motor dysfunction.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Progressive neurologic degeneration with pyramidal motor involvement.
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Progressive neurological degeneration results in flexion contractures of legs and arms"
      explanation: The clinical review links neurologic degeneration to motor contractures and spastic motor manifestations.
  - target: Hypotonia
    description: CNS storage pathology and motor deterioration are associated with hypotonia through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001252 | Hypotonia | Frequent (79-30%)"
      explanation: Orphanet records hypotonia as a frequent fucosidosis phenotype.
  - target: Decreased muscle mass
    description: Progressive neurologic and multisystem disease is associated with decreased muscle mass through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0003199 | Decreased muscle mass | Frequent (79-30%)"
      explanation: Orphanet records decreased muscle mass as a frequent fucosidosis phenotype.
- name: Hypomyelination
  description: >
    CNS fucosidosis storage pathology includes oligodendrocyte loss and reduced
    myelination, supporting white-matter disease and progressive motor
    impairment.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: myelination
    modifier: DECREASED
    term:
      id: GO:0042552
      label: myelination
  locations:
  - preferred_term: brain white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:26537923
    reference_title: The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "oligodendrocyte loss, and hypomyelination throughout the"
    explanation: The canine fucosidosis model shows oligodendrocyte loss and hypomyelination.
  - reference: PMID:11360116
    reference_title: Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI showed diffuse hypomyelination"
    explanation: A human pre-transplant evaluation documented diffuse hypomyelination.
  downstream:
  - target: Spastic tetraplegia
    description: White-matter disease contributes to progressive motor impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002510 | Spastic tetraplegia | Frequent (79-30%)"
      explanation: Orphanet records spastic tetraplegia as a frequent motor phenotype.
  - target: Hearing impairment
    description: CNS white-matter involvement can coincide with auditory pathway abnormalities and hearing impairment, but the causal intermediate is incompletely defined.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:11360116
      reference_title: Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation.
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "auditory brainstem responses and"
      explanation: A human case links diffuse hypomyelination with altered auditory brainstem responses.
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000365 | Hearing impairment | Very frequent (99-80%)"
      explanation: Orphanet records hearing impairment as a very frequent fucosidosis phenotype.
  - target: Abnormal pyramidal sign
    description: White-matter and corticospinal motor involvement can produce pyramidal signs through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0007256 | Abnormal pyramidal sign | Occasional (29-5%)"
      explanation: Orphanet records abnormal pyramidal sign as an occasional fucosidosis phenotype.
- name: Visceral and cutaneous storage disease
  description: >
    Fucose-rich substrate storage in visceral and skin tissues is associated with
    hepatomegaly, hyperhidrosis, angiokeratoma or telangiectatic vascular skin
    abnormalities, hyperkeratosis, and other extracerebral features.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: skin of body
    term:
      id: UBERON:0002097
      label: skin of body
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "accretion of fucose-containing oligosaccharides, glycoproteins, and glycolipids in the brain, liver and skin"
    explanation: The review explicitly places storage material in brain, liver, and skin.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "skin abnormalities also include widespread telangiectasia, skin thickness, hyperhidrosis"
    explanation: The clinical review supports cutaneous disease as part of fucosidosis.
  downstream:
  - target: Hepatomegaly
    description: Visceral storage contributes to liver enlargement.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Storage material in liver tissue.
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hepatomegaly was documented in 20%"
      explanation: The clinical review documents hepatomegaly in fucosidosis.
  - target: Hyperhidrosis
    description: Cutaneous involvement contributes to abnormal sweating.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "skin abnormalities also include widespread telangiectasia, skin thickness, hyperhidrosis"
      explanation: The clinical review lists hyperhidrosis among skin abnormalities.
  - target: Generalized hyperkeratosis
    description: Cutaneous storage disease is associated with generalized hyperkeratosis through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:349
      reference_title: Fucosidosis (Orphanet structured-database record)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0005595 | Generalized hyperkeratosis | Very frequent (99-80%)"
      explanation: Orphanet records generalized hyperkeratosis as a very frequent fucosidosis phenotype.
  - target: Vascular skin abnormality
    description: Skin involvement includes telangiectasia and angiokeratoma.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Telangiectasia and angiokeratoma in skin vessels.
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Dermatological abnormalities were documented in 60% of patient and included telangiectasiae on the skin or conjunctivae and angiokeratoma"
      explanation: The clinical review links cutaneous disease to telangiectasia and angiokeratoma.
  - target: Acrocyanosis
    description: Cutaneous vascular involvement can include acrocyanosis through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "skin abnormalities also include widespread telangiectasia, skin thickness, hyperhidrosis and hypohidrosis, acrocyanosis"
      explanation: The clinical review lists acrocyanosis among fucosidosis skin abnormalities.
  - target: Abnormal nail morphology
    description: Cutaneous involvement can include distal nail changes through incompletely defined intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "distal transverse nail bands"
      explanation: The clinical review documents nail changes as part of the skin phenotype.
- name: Respiratory mucus clearance impairment
  description: >
    Fucosidosis respiratory infections may reflect local airway mucus-clearance
    vulnerability. The clinical review notes intact immune testing in reported
    patients and proposes altered fucose/sialic-acid-dependent mucus
    cross-linking and viscoelasticity as a contributor.
  biological_processes:
  - preferred_term: mucociliary clearance
    modifier: DECREASED
    term:
      id: GO:0120197
      label: mucociliary clearance
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "it was suspected that there could be a local defect in mucus clearance."
    explanation: The review proposes impaired mucus clearance as a contributor to recurrent respiratory infections.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "terminal sugars fucose and sialic acid play a major role in defining the viscoelasticity of mucus."
    explanation: The review gives the proposed glycoconjugate-mucus intermediate.
  downstream:
  - target: Recurrent respiratory infections
    description: Impaired local mucus clearance is suspected to increase recurrent respiratory infections.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Abnormal mucus viscoelasticity and ineffective ciliary clearance.
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Up to 78% of patients experience respiratory tract infections"
      explanation: The clinical review supports frequent respiratory infections in fucosidosis.
- name: Skeletal dysostosis involvement
  description: >
    Fucosidosis includes skeletal involvement with dysostosis multiplex and
    vertebral changes. The direct cellular intermediates between fucose-rich
    storage and skeletal morphology are not specified in the cached evidence.
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "developmental delay associated with psychomotor regression and bone abnormalities"
    explanation: Orphanet definition supports skeletal/bone involvement in fucosidosis.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some patients also have non-specific features of dysostosis multiplex"
    explanation: The clinical review supports dysostosis multiplex as a skeletal manifestation.
  downstream:
  - target: Dysostosis multiplex
    description: Skeletal involvement manifests as dysostosis multiplex.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Some patients also have non-specific features of dysostosis multiplex"
      explanation: The clinical review supports dysostosis multiplex in fucosidosis.
  - target: Anterior beaking of lumbar vertebrae
    description: Vertebral skeletal involvement includes anterior tonguing or beaking.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "An X-ray of the spine shows small thoracolumbar vertebrae with anterior tonguing"
      explanation: The clinical review supports anterior vertebral changes as part of skeletal involvement.
  - target: Kyphosis
    description: Skeletal involvement can include kyphotic/gibbous spinal deformity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "gibbous deformity of lumbar vertebrae"
      explanation: The clinical review supports spinal deformity in fucosidosis.
- name: Ocular storage involvement
  description: >
    Fucosidosis can involve ocular tissues, including conjunctival and retinal
    vessels and corneal clarity. The cached clinical review links storage
    material to ocular vessels and lists corneal opacities in affected patients.
  locations:
  - preferred_term: eye
    term:
      id: UBERON:0000970
      label: eye
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "storage material accumulates in conjunctival, retinal, and skin vessels."
    explanation: The clinical review supports ocular vessel storage involvement.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "corneal opacities in 11%"
    explanation: The clinical review documents corneal opacity in patients.
  downstream:
  - target: Corneal opacity
    description: Ocular storage involvement can include corneal opacity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "corneal opacities in 11%"
      explanation: The clinical review documents corneal opacity in fucosidosis.
phenotypes:
- name: Severe intellectual disability
  frequency: VERY_FREQUENT
  description: Severe cognitive impairment is a core neurodevelopmental manifestation.
  phenotype_term:
    preferred_term: Severe intellectual disability
    term:
      id: HP:0010864
      label: Severe intellectual disability
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010864 | Intellectual disability, severe | Very frequent (99-80%)"
    explanation: Orphanet lists severe intellectual disability as very frequent.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "up to 95% of patients have progressive mental health deterioration"
    explanation: The clinical review supports high-frequency progressive cognitive deterioration.
- name: Global developmental delay
  frequency: VERY_FREQUENT
  description: Developmental delay is typical and may be followed by regression.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001263 | Global developmental delay | Very frequent (99-80%)"
    explanation: Orphanet lists global developmental delay as very frequent.
- name: Brachycephaly
  frequency: VERY_FREQUENT
  description: Craniofacial morphology can include brachycephaly.
  phenotype_term:
    preferred_term: Brachycephaly
    term:
      id: HP:0000248
      label: Brachycephaly
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000248 | Brachycephaly | Very frequent (99-80%)"
    explanation: Orphanet lists brachycephaly as very frequent.
- name: Coarse facial features
  frequency: VERY_FREQUENT
  description: Coarse facial features are a common dysmorphic manifestation.
  phenotype_term:
    preferred_term: Coarse facial features
    term:
      id: HP:0000280
      label: Coarse facial features
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000280 | Coarse facial features | Very frequent (99-80%)"
    explanation: Orphanet lists coarse facial features as very frequent.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical features include coarse facial features"
    explanation: The clinical review lists coarse facial features among the manifestations.
- name: Abnormal facial shape
  frequency: VERY_FREQUENT
  description: Facial dysmorphism is part of the fucosidosis phenotype.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001999 | Abnormal facial shape | Very frequent (99-80%)"
    explanation: Orphanet lists abnormal facial shape as very frequent.
- name: Prominent forehead
  frequency: VERY_FREQUENT
  description: Prominent forehead contributes to the craniofacial presentation.
  phenotype_term:
    preferred_term: Prominent forehead
    term:
      id: HP:0011220
      label: Prominent forehead
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011220 | Prominent forehead | Very frequent (99-80%)"
    explanation: Orphanet lists prominent forehead as very frequent.
- name: Hearing impairment
  frequency: VERY_FREQUENT
  description: Hearing impairment is common and can include sensorineural hearing loss.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000365 | Hearing impairment | Very frequent (99-80%)"
    explanation: Orphanet lists hearing impairment as very frequent.
- name: Hypothyroidism
  frequency: VERY_FREQUENT
  description: Hypothyroidism is listed among frequent endocrine findings in Orphanet.
  phenotype_term:
    preferred_term: Hypothyroidism
    term:
      id: HP:0000821
      label: Hypothyroidism
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000821 | Hypothyroidism | Very frequent (99-80%)"
    explanation: Orphanet lists hypothyroidism as very frequent.
- name: Dysostosis multiplex
  frequency: VERY_FREQUENT
  description: Skeletal involvement includes dysostosis multiplex.
  phenotype_term:
    preferred_term: Dysostosis multiplex
    term:
      id: HP:0000943
      label: Dysostosis multiplex
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000943 | Dysostosis multiplex | Very frequent (99-80%)"
    explanation: Orphanet lists dysostosis multiplex as very frequent.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dysostosis multiplex, and angiokeratoma corporis"
    explanation: The clinical review lists dysostosis multiplex among major features.
- name: Anterior beaking of lumbar vertebrae
  frequency: VERY_FREQUENT
  description: Vertebral changes are part of the skeletal dysostosis pattern.
  phenotype_term:
    preferred_term: Anterior beaking of lumbar vertebrae
    term:
      id: HP:0008430
      label: Anterior beaking of lumbar vertebrae
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008430 | Anterior beaking of lumbar vertebrae | Very frequent (99-80%)"
    explanation: Orphanet lists anterior beaking of lumbar vertebrae as very frequent.
- name: Kyphosis
  frequency: VERY_FREQUENT
  description: Kyphosis is part of the skeletal phenotype.
  phenotype_term:
    preferred_term: Kyphosis
    term:
      id: HP:0002808
      label: Kyphosis
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002808 | Kyphosis | Very frequent (99-80%)"
    explanation: Orphanet lists kyphosis as very frequent.
- name: Hyperhidrosis
  frequency: VERY_FREQUENT
  description: Excessive sweating is a prominent cutaneous/autonomic feature.
  phenotype_term:
    preferred_term: Hyperhidrosis
    term:
      id: HP:0000975
      label: Hyperhidrosis
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000975 | Hyperhidrosis | Very frequent (99-80%)"
    explanation: Orphanet lists hyperhidrosis as very frequent.
- name: Generalized hyperkeratosis
  frequency: VERY_FREQUENT
  description: Generalized hyperkeratosis is listed among cutaneous features.
  phenotype_term:
    preferred_term: Generalized hyperkeratosis
    term:
      id: HP:0005595
      label: Generalized hyperkeratosis
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005595 | Generalized hyperkeratosis | Very frequent (99-80%)"
    explanation: Orphanet lists generalized hyperkeratosis as very frequent.
- name: Hepatomegaly
  frequency: VERY_FREQUENT
  description: Liver enlargement reflects visceral involvement.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002240 | Hepatomegaly | Very frequent (99-80%)"
    explanation: Orphanet lists hepatomegaly as very frequent.
- name: Failure to thrive
  frequency: VERY_FREQUENT
  description: Growth failure or poor weight gain is common.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001508 | Failure to thrive | Very frequent (99-80%)"
    explanation: Orphanet lists failure to thrive as very frequent.
- name: Mucopolysacchariduria
  frequency: VERY_FREQUENT
  description: Abnormal urinary storage products can resemble mucopolysaccharide storage disease biochemically.
  phenotype_term:
    preferred_term: Mucopolysacchariduria
    term:
      id: HP:0008155
      label: Mucopolysacchariduria
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008155 | Mucopolysacchariduria | Very frequent (99-80%)"
    explanation: Orphanet lists mucopolysacchariduria as very frequent.
- name: Lipoatrophy
  frequency: VERY_FREQUENT
  description: Lipoatrophy is listed by Orphanet among very frequent manifestations.
  phenotype_term:
    preferred_term: Lipoatrophy
    term:
      id: HP:0100578
      label: Lipoatrophy
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100578 | Lipoatrophy | Very frequent (99-80%)"
    explanation: Orphanet lists lipoatrophy as very frequent.
- name: Seizure
  frequency: FREQUENT
  description: Seizures occur in a substantial fraction of patients.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Frequent (79-30%)"
    explanation: Orphanet lists seizures as frequent.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "seizures may occur in 38% of patients"
    explanation: The clinical review provides quantitative support for the frequent band.
- name: Hypotonia
  frequency: FREQUENT
  description: Hypotonia is a motor manifestation.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001252 | Hypotonia | Frequent (79-30%)"
    explanation: Orphanet lists hypotonia as frequent.
- name: Spasticity
  frequency: FREQUENT
  description: Progressive pyramidal motor involvement can produce spasticity.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001257 | Spasticity | Frequent (79-30%)"
    explanation: Orphanet lists spasticity as frequent.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "estimated to affect up to 40% of all fucosidosis cases"
    explanation: The review supports spasticity within the frequent band.
- name: Spastic tetraplegia
  frequency: FREQUENT
  description: Some patients develop spastic quadriparetic motor impairment.
  phenotype_term:
    preferred_term: Spastic tetraplegia
    term:
      id: HP:0002510
      label: Spastic tetraplegia
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002510 | Spastic tetraplegia | Frequent (79-30%)"
    explanation: Orphanet lists spastic tetraplegia as frequent.
- name: Decreased muscle mass
  frequency: FREQUENT
  description: Decreased muscle mass is part of the motor or nutritional phenotype.
  phenotype_term:
    preferred_term: Decreased muscle mass
    term:
      id: HP:0003199
      label: Decreased muscle mass
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003199 | Decreased muscle mass | Frequent (79-30%)"
    explanation: Orphanet lists decreased muscle mass as frequent.
- name: Abnormality of the cardiovascular system
  frequency: FREQUENT
  description: Cardiovascular abnormalities are reported in fucosidosis.
  phenotype_term:
    preferred_term: Abnormality of the cardiovascular system
    term:
      id: HP:0001626
      label: Abnormality of the cardiovascular system
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001626 | Abnormality of the cardiovascular system | Frequent (79-30%)"
    explanation: Orphanet lists cardiovascular abnormality as frequent.
- name: Abnormality of the gallbladder
  frequency: FREQUENT
  description: Gallbladder involvement is listed by Orphanet.
  phenotype_term:
    preferred_term: Abnormality of the gallbladder
    term:
      id: HP:0005264
      label: Abnormality of the gallbladder
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005264 | Abnormality of the gallbladder | Frequent (79-30%)"
    explanation: Orphanet lists gallbladder abnormality as frequent.
- name: Recurrent respiratory infections
  frequency: FREQUENT
  description: Recurrent respiratory tract infections are common and contribute to mortality.
  phenotype_term:
    preferred_term: Recurrent respiratory infections
    term:
      id: HP:0002205
      label: Recurrent respiratory infections
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Up to 78% of patients experience respiratory tract infections"
    explanation: >
      The clinical review supports recurrent respiratory infections as a frequent
      fucosidosis phenotype.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "around 60% of patients die secondary to respiratory infections and neurological deteriorations"
    explanation: >
      The same review supports respiratory infections as clinically important
      contributors to fucosidosis mortality.
- name: Vascular skin abnormality
  frequency: FREQUENT
  description: Vascular skin findings include telangiectasia and angiokeratoma.
  phenotype_term:
    preferred_term: Vascular skin abnormality
    term:
      id: HP:0011276
      label: Vascular skin abnormality
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011276 | Vascular skin abnormality | Frequent (79-30%)"
    explanation: Orphanet lists vascular skin abnormality as frequent.
  - reference: PMID:38053939
    reference_title: Long-term outcomes in two adult siblings with Fucosidosis - Diagnostic odyssey and clinical manifestations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "angiokeratomas with differing severity."
    explanation: Adult sibling follow-up documents angiokeratomas as typical fucosidosis features.
- name: Corneal opacity
  frequency: FREQUENT
  description: Corneal opacity is reported as an ocular manifestation.
  phenotype_term:
    preferred_term: Corneal opacity
    term:
      id: HP:0007957
      label: Corneal opacity
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007957 | Corneal opacity | Frequent (79-30%)"
    explanation: Orphanet lists corneal opacity as frequent.
- name: Abnormality of the dentition
  frequency: OCCASIONAL
  description: Dental abnormalities occur in a subset of patients.
  phenotype_term:
    preferred_term: Abnormality of the dentition
    term:
      id: HP:0000164
      label: Abnormality of the dentition
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000164 | Abnormality of the dentition | Occasional (29-5%)"
    explanation: Orphanet lists dentition abnormality as occasional.
- name: Acrocyanosis
  frequency: OCCASIONAL
  description: Peripheral cyanotic discoloration can occur.
  phenotype_term:
    preferred_term: Acrocyanosis
    term:
      id: HP:0001063
      label: Acrocyanosis
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001063 | Acrocyanosis | Occasional (29-5%)"
    explanation: Orphanet lists acrocyanosis as occasional.
- name: Abnormal nail morphology
  frequency: OCCASIONAL
  description: Nail abnormalities occur in a subset of patients.
  phenotype_term:
    preferred_term: Abnormal nail morphology
    term:
      id: HP:0001597
      label: Abnormal nail morphology
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001597 | Abnormality of the nail | Occasional (29-5%)"
    explanation: Orphanet lists nail abnormality as occasional.
- name: Cardiomegaly
  frequency: OCCASIONAL
  description: Cardiomegaly is reported occasionally.
  phenotype_term:
    preferred_term: Cardiomegaly
    term:
      id: HP:0001640
      label: Cardiomegaly
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001640 | Cardiomegaly | Occasional (29-5%)"
    explanation: Orphanet lists cardiomegaly as occasional.
- name: Abnormal pyramidal sign
  frequency: OCCASIONAL
  description: Pyramidal signs reflect corticospinal tract involvement.
  phenotype_term:
    preferred_term: Abnormal pyramidal sign
    term:
      id: HP:0007256
      label: Abnormal pyramidal sign
  evidence:
  - reference: ORPHA:349
    reference_title: Fucosidosis (Orphanet structured-database record)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007256 | Abnormal pyramidal sign | Occasional (29-5%)"
    explanation: Orphanet lists abnormal pyramidal sign as occasional.
biochemical:
- name: Alpha-L-fucosidase activity
  presence: Reduced
  context: Diagnostic enzyme assay
  notes: >
    Affected individuals have deficient alpha-L-fucosidase activity in
    leukocytes, fibroblasts, or other assayed cells.
  readouts:
  - target: FUCA1 alpha-L-fucosidase deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Reduced alpha-L-fucosidase activity directly reports the primary FUCA1
      lysosomal hydrolase deficiency.
    evidence:
    - reference: PMID:1873910
      reference_title: Defective expression of alpha-L-fucosidase by lymphoid cells of a fucosidosis patient.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "negligible catalytic activity as compared with the mean of 19 control cultures."
      explanation: Patient lymphoid-cell assays directly support low alpha-L-fucosidase catalytic activity as a readout of the root enzyme deficiency.
  evidence:
  - reference: PMID:1873910
    reference_title: Defective expression of alpha-L-fucosidase by lymphoid cells of a fucosidosis patient.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "16-fold lower extracellular alpha-L-fucosidase"
    explanation: Patient lymphoid cells showed markedly reduced enzyme protein.
- name: Urinary fucose-rich oligosaccharides and glycopeptides
  presence: Elevated
  context: Biochemical storage marker
  notes: >
    Urine may show excess fucosylated glycopeptides, glycoasparagines, and
    oligosaccharides.
  readouts:
  - target: Fucose-rich glycoconjugate lysosomal storage
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Increased urinary fucose-rich oligosaccharides and glycopeptides report
      the fucosylated glycoconjugate storage burden caused by alpha-L-fucosidase
      deficiency.
    evidence:
    - reference: PMID:33266441
      reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients affected with fucosidosis excrete a large amount of glycopeptide in the urine"
      explanation: The review supports urinary fucosylated glycopeptide excretion as a diagnostic readout of fucose-rich glycoconjugate storage.
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients affected with fucosidosis excrete a large amount of glycopeptide in the urine"
    explanation: The review supports urinary excretion of abnormal fucosylated storage products.
diagnosis:
- name: FUCA1 molecular genetic testing
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  description: >
    Molecular testing for biallelic pathogenic FUCA1 variants confirms the
    diagnosis when enzyme deficiency and the clinical phenotype are compatible.
  results: Biallelic pathogenic FUCA1 variants support molecular diagnosis.
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FUCA1 sequence analysis detects most of the known pathogenic changes"
    explanation: The review supports FUCA1 sequencing as a molecular diagnostic approach.
- name: Alpha-L-fucosidase enzyme testing
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  description: >
    Biochemical enzyme testing in plasma, leukocytes, or fibroblasts can
    demonstrate deficient alpha-L-fucosidase activity.
  results: Low alpha-L-fucosidase activity supports fucosidosis.
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biochemical testing is the first-line test and the preferred method for confirming the diagnosis"
    explanation: The review supports biochemical enzyme testing as first-line confirmation.
- name: Brain MRI globus pallidus T2 hypointensity
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  description: >
    Brain MRI can show globus pallidus signal abnormalities, including marked
    T2/FLAIR hypointensity with T1 hyperintensity, a feature described as
    distinctive for fucosidosis and helpful for distinguishing it from other
    neurometabolic disorders.
  results: Globus pallidus T2/FLAIR hypointensity supports fucosidosis in the appropriate clinical context.
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This unique-for-fucosidosis feature manifests as marked hypointensity on T2/FLAIR sequences"
    explanation: >
      The review identifies marked globus pallidus T2/FLAIR hypointensity as a
      distinctive fucosidosis MRI feature.
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "low signal of the globus pallidus may help distinguish it from other neurometabolic disorders"
    explanation: >
      The review supports the diagnostic value of globus pallidus low signal in
      distinguishing fucosidosis from other neurometabolic disorders.
treatments:
- name: Supportive care
  description: >
    Supportive multidisciplinary management addresses motor impairment, feeding,
    orthopedic, ophthalmologic, cardiologic, neurologic, neuropsychiatric, and
    developmental complications.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:33266441
    reference_title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cornerstone of management is generally supportive"
    explanation: The clinical review identifies supportive multidisciplinary care as the management cornerstone.
  - reference: PMID:27491218
    reference_title: Therapy Development for the Lysosomal Storage Disease Fucosidosis using the Canine Animal Model.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "supportive care are limited."
    explanation: The therapy review supports supportive care as the main non-targeted management option.
- name: Hematopoietic stem cell transplantation
  description: >
    Hematopoietic stem cell transplantation has been used in a small number of
    carefully selected patients and may delay disease progression when performed
    early, but risks and exclusion criteria limit use.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
  target_phenotypes:
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  - preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  target_mechanisms:
  - target: FUCA1 alpha-L-fucosidase deficiency
    treatment_effect: RESTORES
    description: Donor-derived hematopoietic cells can provide enzyme cross-correction.
    evidence:
    - reference: PMID:11360116
      reference_title: Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Follow-up showed a progressive rise of enzymatic levels."
      explanation: Post-transplant follow-up showed rising alpha-L-fucosidase enzyme levels.
  evidence:
  - reference: PMID:11360116
    reference_title: Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "improved, as confirmed by evaluation of evoked potentials and by MRI scanning."
    explanation: The reported child had improved psychomotor development after unrelated donor bone marrow transplantation.
  - reference: PMID:27491218
    reference_title: Therapy Development for the Lysosomal Storage Disease Fucosidosis using the Canine Animal Model.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "delaying the disease course."
    explanation: The therapy review frames hematopoietic transplant as the available disease-course-delaying option.
- name: Intracisternal enzyme replacement therapy
  description: >
    Intracisternal enzyme replacement is preclinical and has reduced
    neuropathology in canine fucosidosis models, but more complete and sustained
    correction is needed before it can be considered an established human
    treatment.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: FUCA1 alpha-L-fucosidase deficiency
    treatment_effect: RESTORES
    description: Recombinant alpha-L-fucosidase aims to replace deficient enzyme activity in the CNS.
    evidence:
    - reference: PMID:26537923
      reference_title: The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis.
      supports: PARTIAL
      evidence_source: MODEL_ORGANISM
      snippet: "recombinant canine α-L-fucosidase delivered"
      explanation: The canine study tested CNS delivery of recombinant alpha-L-fucosidase.
  evidence:
  - reference: PMID:26537923
    reference_title: The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis.
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "reduced severity of fucosidosis neuropathology with partial"
    explanation: The canine model supports partial preclinical benefit, not an established human therapy.
references:
- reference: ORPHA:349
  title: Fucosidosis
  found_in:
  - Fucosidosis-deep-research-fallback.md
- reference: PMID:11360116
  title: Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation.
  found_in:
  - Fucosidosis-deep-research-fallback.md
- reference: PMID:1873910
  title: Defective expression of alpha-L-fucosidase by lymphoid cells of a fucosidosis patient.
  found_in:
  - Fucosidosis-deep-research-fallback.md
- reference: PMID:26537923
  title: The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis.
  found_in:
  - Fucosidosis-deep-research-fallback.md
- reference: PMID:27491075
  title: A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease.
  found_in:
  - Fucosidosis-deep-research-fallback.md
- reference: PMID:27491218
  title: Therapy Development for the Lysosomal Storage Disease Fucosidosis using the Canine Animal Model.
  found_in:
  - Fucosidosis-deep-research-fallback.md
- reference: PMID:33266441
  title: Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
  found_in:
  - Fucosidosis-deep-research-fallback.md
- reference: PMID:38053939
  title: Long-term outcomes in two adult siblings with Fucosidosis - Diagnostic odyssey and clinical manifestations.
  found_in:
  - Fucosidosis-deep-research-fallback.md
- reference: PMID:39796208
  title: "Fucosidosis: A Review of a Rare Disease."
  found_in:
  - Fucosidosis-deep-research-fallback.md
📚

References & Deep Research

References

9
ORPHA:349
Fucosidosis
No top-level findings curated for this source.
PMID:11360116
Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation.
No top-level findings curated for this source.
PMID:1873910
Defective expression of alpha-L-fucosidase by lymphoid cells of a fucosidosis patient.
No top-level findings curated for this source.
PMID:26537923
The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis.
No top-level findings curated for this source.
PMID:27491075
A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease.
No top-level findings curated for this source.
PMID:27491218
Therapy Development for the Lysosomal Storage Disease Fucosidosis using the Canine Animal Model.
No top-level findings curated for this source.
PMID:33266441
Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
No top-level findings curated for this source.
PMID:38053939
Long-term outcomes in two adult siblings with Fucosidosis - Diagnostic odyssey and clinical manifestations.
No top-level findings curated for this source.
PMID:39796208
Fucosidosis: A Review of a Rare Disease.
No top-level findings curated for this source.

Deep Research

1
Fucosidosis Deep Research Fallback ▸

Fucosidosis Deep Research Fallback

Provider Attempts

  • 2026-05-04T15:50Z: just research-disorder falcon Fucosidosis --max-tokens 6000 failed before provider execution because this deep-research-client version does not accept --max-tokens.
  • 2026-05-04T15:51Z: just research-disorder falcon Fucosidosis produced no output after startup during the bounded wait and did not respond to stdin interrupt, so the provider process was terminated with SIGTERM.
  • 2026-05-04T15:53Z: just research-disorder openai Fucosidosis also produced no output after startup during the bounded wait and was terminated with SIGTERM.

No provider-generated deep-research narrative was available within the bounded runtime. Curation therefore proceeded from generated structured Orphanet evidence and fetched PubMed caches, without hand-editing any references_cache/*.md files.

Evidence Scope Used For Curation

  • ORPHA:349 structured record for the disease definition, exact MONDO and OMIM mappings, autosomal recessive inheritance, FUCA1 disease-gene association, epidemiology, age of onset, and all structured HPO phenotype rows.
  • PMID:33266441 for the detailed human clinical review and case series covering FUCA1 genetics, alpha-L-fucosidase deficiency, fucose-rich substrate storage, phenotype frequencies, diagnostic approach, supportive care, and HSCT experience.
  • PMID:39796208 for a recent review summarizing the FUCA1-to-enzyme-deficiency mechanism, lysosomal substrate accumulation, neuroinflammation, neuronal loss, and investigational treatment landscape.
  • PMID:1873910 for patient lymphoid-cell evidence of markedly reduced alpha-L-fucosidase protein and catalytic activity.
  • PMID:27491075 for a Fuca1-deficient mouse model showing lysosomal storage, enlarged CNS lysosomal compartments, neuroinflammation, Purkinje-cell loss, astrogliosis, and behavioral deficits.
  • PMID:26537923 for the canine fucosidosis enzyme-replacement experiment showing CNS neuropathology, oligodendrocyte loss, hypomyelination, and partial neuropathologic improvement after intracisternal recombinant enzyme.
  • PMID:11360116 for human unrelated donor bone marrow transplantation follow-up showing rising enzymatic levels and improved psychomotor development.
  • PMID:27491218 for the fucosidosis therapy-development review describing supportive care limitations and hematopoietic transplant as the available disease-course-delaying intervention.
  • PMID:38053939 for long-term adult sibling follow-up documenting clinical heterogeneity, slow neurologic deterioration, ataxia, angiokeratomas, and FUCA1 molecular diagnosis.

Curation Conclusions

The accepted disease model is biallelic FUCA1 pathogenic variation causing lysosomal alpha-L-fucosidase deficiency. The enzyme defect blocks degradation of fucosylated glycoproteins, glycosphingolipids, and oligosaccharides, producing lysosomal storage in neural, visceral, and cutaneous tissues. CNS storage causes lysosomal expansion, secondary storage, neuroinflammation, neuronal loss, oligodendrocyte loss, and hypomyelination, which explain progressive developmental impairment, severe intellectual disability, seizures, spasticity, and hearing impairment. Visceral and cutaneous storage contributes to hepatomegaly, hyperhidrosis, hyperkeratosis, and vascular skin lesions. Current management is mainly supportive, while carefully selected early hematopoietic stem cell transplantation has limited human evidence for enzyme restoration and clinical stabilization or improvement. Enzyme replacement remains preclinical in the available evidence.